B Zethelius1, L Byberg, C N Hales, H Lithell, C Berne. 1. Department of Public Health and Caring Sciences/Section of Geriatrics, Uppsala University, Uppsala, Sweden. bjorn.zethelius@pubcare.uu.se
Abstract
AIMS/HYPOTHESIS: Defects in insulin secretion and insulin action, resulting in compensatory hyperinsulinaemia, are the major abnormalities in the development of Type 2 diabetes mellitus (Type 2 diabetes). The most frequently used conventional immunoreactive assays for insulin cross-react with proinsulin. In short-term studies (<5 years), proinsulin predicts the development of Type 2 diabetes. We studied, with a 27-year follow-up, the longitudinal relationships between intact proinsulin, 32-33 split proinsulin, specific and immunoreactive insulin (IRI), acute insulin response (AIR) after an intravenous glucose load and the development of Type 2 diabetes in a population-based cohort of 50-year-old men. METHODS: Fasting peptide concentrations were measured in plasma samples, stored since 1970-73 using specific two-site immunometric assays. IRI was measured at baseline using radioimmunoassay. Associations between development of Type 2 diabetes and predictor variables, were analysed with logistic regression. Results are shown as odds ratios (ORs) with their 95% confidence intervals (CIs) for a one standard deviation increase in a predictor variable. RESULTS: Cumulative incidence of Type 2 diabetes was 33% over 27 years of follow-up. Intact proinsulin (OR, 1.57, CI, 1.16-2.14), and 32-33 split proinsulin (OR, 1.70, CI, 1.20-2.39) were associated with development of Type 2 diabetes, independent of AIR, adjusted for BMI and fasting glucose, whereas specific insulin was not (OR, 1.31, CI, 0.98-1.77), nor was IRI (OR, 1.25, CI, 0.96-1.63). Proinsulin and AIR interacted in the development of Type 2 diabetes (p<0.05). CONCLUSION/ INTERPRETATION: Proinsulin predicts the development of Type 2 diabetes mellitus over a 27-year period.
AIMS/HYPOTHESIS: Defects in insulin secretion and insulin action, resulting in compensatory hyperinsulinaemia, are the major abnormalities in the development of Type 2 diabetes mellitus (Type 2 diabetes). The most frequently used conventional immunoreactive assays for insulin cross-react with proinsulin. In short-term studies (<5 years), proinsulin predicts the development of Type 2 diabetes. We studied, with a 27-year follow-up, the longitudinal relationships between intact proinsulin, 32-33 split proinsulin, specific and immunoreactive insulin (IRI), acute insulin response (AIR) after an intravenous glucose load and the development of Type 2 diabetes in a population-based cohort of 50-year-old men. METHODS: Fasting peptide concentrations were measured in plasma samples, stored since 1970-73 using specific two-site immunometric assays. IRI was measured at baseline using radioimmunoassay. Associations between development of Type 2 diabetes and predictor variables, were analysed with logistic regression. Results are shown as odds ratios (ORs) with their 95% confidence intervals (CIs) for a one standard deviation increase in a predictor variable. RESULTS: Cumulative incidence of Type 2 diabetes was 33% over 27 years of follow-up. Intact proinsulin (OR, 1.57, CI, 1.16-2.14), and 32-33 split proinsulin (OR, 1.70, CI, 1.20-2.39) were associated with development of Type 2 diabetes, independent of AIR, adjusted for BMI and fasting glucose, whereas specific insulin was not (OR, 1.31, CI, 0.98-1.77), nor was IRI (OR, 1.25, CI, 0.96-1.63). Proinsulin and AIR interacted in the development of Type 2 diabetes (p<0.05). CONCLUSION/ INTERPRETATION:Proinsulin predicts the development of Type 2 diabetes mellitus over a 27-year period.
Authors: M E Røder; B Dinesen; S G Hartling; P Houssa; H Vestergaard; F Sodoyez-Goffaux; C Binder Journal: Diabetes Care Date: 1999-04 Impact factor: 19.112
Authors: W J Sobey; S F Beer; C A Carrington; P M Clark; B H Frank; I P Gray; S D Luzio; D R Owens; A E Schneider; K Siddle Journal: Biochem J Date: 1989-06-01 Impact factor: 3.857
Authors: S Lillioja; D M Mott; M Spraul; R Ferraro; J E Foley; E Ravussin; W C Knowler; P H Bennett; C Bogardus Journal: N Engl J Med Date: 1993-12-30 Impact factor: 91.245
Authors: Quinn Dufurrena; Nils Bäck; Richard E Mains; Louis Hodgson; Herbert Tanowitz; Prashant Mandela; Elizabeth Eipper; Regina Kuliawat Journal: J Mol Endocrinol Date: 2018-11-01 Impact factor: 5.098
Authors: Chong Wee Liew; Anke Assmann; Andrew T Templin; Jeffrey C Raum; Kathryn L Lipson; Sindhu Rajan; Guifen Qiang; Jiang Hu; Dan Kawamori; Iris Lindberg; Louis H Philipson; Nahum Sonenberg; Allison B Goldfine; Doris A Stoffers; Raghavendra G Mirmira; Fumihiko Urano; Rohit N Kulkarni Journal: Proc Natl Acad Sci U S A Date: 2014-05-19 Impact factor: 11.205
Authors: Vera Schmid; Robert Wagner; Corinna Sailer; Louise Fritsche; Konstantinos Kantartzis; Andreas Peter; Martin Heni; Hans-Ulrich Häring; Norbert Stefan; Andreas Fritsche Journal: Diabetologia Date: 2017-08-24 Impact factor: 10.122